The recognition of the prominent role of the cyclin D–CDK4/6 complex in HR+ BC and the fact that the Rb pathway generally remains functional in these tumors made CDK4/6 inhibitors (CDK4/6i) particularly attractive in this subset of BC [14]. This evidence concerns the gene CDK4 and breast cancer.